INCY's Q4 Earnings Miss Mark, Revenues Beat on Higher Product Sales

Incyte Corporation (INCY) reported fourth-quarter 2024 adjusted earnings of $1.43 per share, which missed the Zacks Consensus Estimate of $1.53. The company had recorded earnings of $1.06 per share in the year-ago quarter.See the Zacks Earnings Calendar to stay ahead of market-making news.Total revenues in the fourth quarter were $1.18 billion, which grew 16% year over year, driven by the sustained performance of its lead drug, Jakafi (ruxolitinib), and increased sales of Opzelura (ruxolitinib) cream on str ...